clinical trial · NCT06109467
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 36
GastroEsophageal CancerGastric CancerNeratinibTrastuzumabOxaliplatin5-Fluorouracil + leucovorinPembrolizumab
brief summary
The purpose of the study is to test the effects, both good and bad, of the research study drug Neratinib in combination with Trastuzumab, Pembrolizumab and FOLFOX chemotherapy. This study will also look at the safety of Neratinib in combination with Trastuzumab, Pembrolizumab and FOLFOX in HER2 overexpressing Gastroesophageal cancers.
started
Jan 12, 2024
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
Feb 9, 2026
official title
A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol